Heron Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Good afternoon. Thank you very much for joining us here today. Next up presenting we have Heron Therapeutics and presenting for Heron will be Barry Quart, the CEO. Heron will have a breakout session in Astor Suite 1 afterwards.
Barry, it's been a busy week for you guys with a lot of good news, so look forward to hearing your presentation. Thank you.
Thanks very much. Always a pleasure to be here. Thanks for the opportunity again. So yes, we have a lot of news the last couple days. We will certainly go through all that. Of course, start with the usual forward-looking statements.
And then just a quick reminder: the Company has two main areas of focus. One is chemotherapy-induced nausea and vomiting with two marketed products: SUSTOL and CINVANTI. We will talk a little bit about those later on.
But we will focus attention mostly on HTX-011, which we recently put out a notice that we have refiled to the FDA. We have had very good
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |